Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,895.20
(
0.09%
)
Dow Jones
49,149.38
(
-0.59%
)
Brent Oil
93.38
(
-1.72%
)
Bitcoin
78,147.10
(
2.38%
)
News Focus
News Focus
Post# of 257433
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122881
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 184709

Wednesday, 06/28/2023 1:37:05 PM

Wednesday, June 28, 2023 1:37:05 PM

Post# of 257433
PFE/OPK—FDA approves Ngenla weekly treatment_for growth-hormone deficiency in children:

https://finance.yahoo.com/news/fda-approves-pfizer-ngenla-long-104500067.html

The approval is based on Ngenla’s showing non-inferiority to PFE’s daily Genotropin. Genotropin had annualized worldwide sales of ~$600M in 1Q23, despite competition from ASND’s Skytrofa (#msg-165622237).

The Ngenla BLA received a CRL in Jan 2022 for undisclosed reasons (#msg-167595039). PFE and OPK inked a partnership deal for commercial development of hGH in 2014 (#msg-109075402).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today